AST

Asterias Biotherapeutics, Inc. (AST)

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:AST
DataOraFonteTitoloSimboloCompagnia
20/03/201922:07Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)AMEX:ASTAsterias Biotherapeutics Common Series A
20/03/201911:02Edgar (US Regulatory)Notice of Effectiveness (effect)AMEX:ASTAsterias Biotherapeutics Common Series A
14/03/201919:55Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)AMEX:ASTAsterias Biotherapeutics Common Series A
14/03/201919:55Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)AMEX:ASTAsterias Biotherapeutics Common Series A
12/03/201922:00Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:ASTAsterias Biotherapeutics Common Series A
12/03/201921:52Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)AMEX:ASTAsterias Biotherapeutics Common Series A
08/03/201922:07Edgar (US Regulatory)Current Report Filing (8-k)AMEX:ASTAsterias Biotherapeutics Common Series A
08/03/201921:18Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...AMEX:ASTAsterias Biotherapeutics Common Series A
01/03/201922:34Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)AMEX:ASTAsterias Biotherapeutics Common Series A
04/02/201923:26Edgar (US Regulatory)Proxy Statement - Merger or Acquistion (definitive) (defm14a)AMEX:ASTAsterias Biotherapeutics Common Series A
24/01/201913:00GlobeNewswire Inc.Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord InjuryAMEX:ASTAsterias Biotherapeutics Common Series A
04/01/201914:00GlobeNewswire Inc.BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech...AMEX:ASTAsterias Biotherapeutics Common Series A
27/11/201813:00GlobeNewswire Inc.Asterias Biotherapeutics Announces Fourth Patient Dosed in First-in-Human Clinical Study of Immunotherapy VAC2 in Non-Small C...AMEX:ASTAsterias Biotherapeutics Common Series A
09/11/201822:10GlobeNewswire Inc.Asterias Biotherapeutics Reports Third Quarter ResultsAMEX:ASTAsterias Biotherapeutics Common Series A
09/11/201822:04Edgar (US Regulatory)Quarterly Report (10-q)AMEX:ASTAsterias Biotherapeutics Common Series A
08/11/201812:35Business WireBioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy CompanyAMEX:ASTAsterias Biotherapeutics Common Series A
08/11/201812:30Business WireBioTime Reports Third Quarter 2018 Financial Results and Provides Business UpdateAMEX:ASTAsterias Biotherapeutics Common Series A
02/11/201812:00GlobeNewswire Inc.Asterias Biotherapeutics to Report Third Quarter 2018 Results on November 12, 2018AMEX:ASTAsterias Biotherapeutics Common Series A
31/10/201814:45GlobeNewswire Inc.Asterias Biotherapeutics Announces Positive Outcome from Data Review from OPC1 Spinal Cord Injury StudyAMEX:ASTAsterias Biotherapeutics Common Series A
01/10/201813:00GlobeNewswire Inc.Asterias Biotherapeutics Announces Facilities and IP License Option AgreementsAMEX:ASTAsterias Biotherapeutics Common Series A
20/09/201813:00GlobeNewswire Inc.FDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Cli...AMEX:ASTAsterias Biotherapeutics Common Series A
12/09/201813:00GlobeNewswire Inc.Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord InjuryAMEX:ASTAsterias Biotherapeutics Common Series A
04/09/201813:00GlobeNewswire Inc.Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 ...AMEX:ASTAsterias Biotherapeutics Common Series A
29/08/201813:00GlobeNewswire Inc.Asterias Biotherapeutics’ CEO Michael Mulroy to Participate on Regenerative Medicine Therapies Panel at the B. Riley FBR He...AMEX:ASTAsterias Biotherapeutics Common Series A
09/08/201822:10GlobeNewswire Inc.Asterias Biotherapeutics Reports Second Quarter Financial Results and Recent Development ProgressAMEX:ASTAsterias Biotherapeutics Common Series A
31/07/201813:00GlobeNewswire Inc.Asterias Provides 12 Month Cohort 3 and 4 Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord InjuryAMEX:ASTAsterias Biotherapeutics Common Series A
26/07/201813:00GlobeNewswire Inc.Asterias Biotherapeutics to Report Second Quarter 2018 Results on August 9, 2018AMEX:ASTAsterias Biotherapeutics Common Series A
17/07/201813:00GlobeNewswire Inc.Asterias Provides Six Month Data Readout for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord InjuryAMEX:ASTAsterias Biotherapeutics Common Series A
12/07/201813:00GlobeNewswire Inc.Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Strok...AMEX:ASTAsterias Biotherapeutics Common Series A
11/07/201813:00GlobeNewswire Inc.Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Cli...AMEX:ASTAsterias Biotherapeutics Common Series A
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:AST
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network